{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:11:11Z","timestamp":1791231071027,"version":"4.1.0"},"reference-count":70,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2022.2578","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T11:15:17Z","timestamp":1659957317000},"source":"Crossref","is-referenced-by-count":4,"title":["Association between CA 15\u20113 and progression of interstitial lung disease in a case of coexisting systemic sclerosis and recurrent breast cancer: A case report"],"prefix":"10.3892","volume":"17","author":[{"given":"Masahiro","family":"Ohara","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Koi","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunari","family":"Sasada","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kajitani","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seishi","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Section of Pathological Research and Laboratory, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Takata","sequence":"additional","affiliation":[{"name":"Section of Pathological Research and Laboratory, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Section of Pathological Research and Laboratory, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Nagata","sequence":"additional","affiliation":[{"name":"Section of Pathological Research and Laboratory, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie","family":"Sumita","sequence":"additional","affiliation":[{"name":"Section of Pathological Research and Laboratory, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaita","family":"Imachi","sequence":"additional","affiliation":[{"name":"Section of Pathological Research and Laboratory, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Section of Pathological Research and Laboratory, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Daimaru","sequence":"additional","affiliation":[{"name":"Section of Pathological Research and Laboratory, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima 738\u20118503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima 734\u20118553, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"key20221010114626_b1-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","article-title":"National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers","volume":"54","author":"Sturgeon","year":"2008","journal-title":"Clin Chem"},{"key":"key20221010114626_b2-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/s0009-9120(00)00201-0","article-title":"Biochemical markers in breast cancer: Which ones are clinically useful?","volume":"34","author":"Duffy","year":"2001","journal-title":"Clin Biochem"},{"key":"key20221010114626_b3-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1373\/clinchem.2004.046227","article-title":"Predictive markers in breast and other cancers: A review","volume":"51","author":"Duffy","year":"2005","journal-title":"Clin Chem"},{"key":"key20221010114626_b4-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acc.2015.05.001","article-title":"Biomarkers in breast cancer: Where Are we and where are we going?","volume":"71","author":"Duffy","year":"2015","journal-title":"Adv Clin Chem"},{"key":"key20221010114626_b5-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.cca.2010.08.039","article-title":"CA 15-3: Uses and limitation as a biomarker for breast cancer","volume":"411","author":"Duffy","year":"2010","journal-title":"Clin Chim Acta"},{"key":"key20221010114626_b6-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"S854","DOI":"10.1136\/ard.50.suppl_4.854","article-title":"Clinical aspects of systemic sclerosis (scleroderma)","volume":"50 (Suppl 4)","author":"Silver","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"key20221010114626_b7-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: A prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J Clin Invest"},{"key":"key20221010114626_b8-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"iii40","DOI":"10.1093\/rheumatology\/kep109","article-title":"Pulmonary complications: One of the most challenging complications of systemic sclerosis","volume":"48 (Suppl 3)","author":"Wells","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"key20221010114626_b9-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20221010114626_b10-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1440-1843.2009.01600.x","article-title":"Non-invasive biomarkers in pulmonary fibrosis","volume":"14","author":"Prasse","year":"2009","journal-title":"Respirology"},{"key":"key20221010114626_b11-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.resinv.2012.02.001","article-title":"Utility of KL-6\/MUC1 in the clinical management of interstitial lung diseases","volume":"50","author":"Ishikawa","year":"2012","journal-title":"Respir Investig"},{"key":"key20221010114626_b12-MCO-17-4-02578","first-page":"203","article-title":"Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma","volume":"18","author":"Kohno","year":"1988","journal-title":"Jpn J Clin Oncol"},{"key":"key20221010114626_b13-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/ijc.26007","article-title":"Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer","volume":"130","author":"Tanaka","year":"2012","journal-title":"Int J Cancer"},{"key":"key20221010114626_b14-MCO-17-4-02578","first-page":"107","article-title":"Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors","volume":"24","author":"Yamasaki","year":"2004","journal-title":"Int J Oncol"},{"key":"key20221010114626_b15-MCO-17-4-02578","first-page":"54","article-title":"Serum CA 15-3 is increased in pulmonary fibrosis","volume":"26","author":"Ricci","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"645","key":"key20221010114626_b16-MCO-17-4-02578","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.5.645","article-title":"Elevated circulating CA 15.3 levels in a subset of systemic sclerosis with severe lung involvement","volume":"134","author":"Valerio Marzano","year":"1998","journal-title":"Arch Dermatol"},{"key":"key20221010114626_b17-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ejim.2013.04.004","article-title":"Carbohydrate antigen 15.3 as a serum biomarker of interstitial lung disease in systemic sclerosis patients","volume":"24","author":"Celeste","year":"2013","journal-title":"Eur J Intern Med"},{"key":"key20221010114626_b18-MCO-17-4-02578","author":"Greene"},{"key":"key20221010114626_b19-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","article-title":"Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer","volume":"183","author":"Hackshaw","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"key20221010114626_b20-MCO-17-4-02578","first-page":"198","article-title":"Systemic sclerosis: An update","volume":"66","author":"Varga","year":"2008","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"key20221010114626_b21-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: A study from the EULAR scleroderma trials and research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20221010114626_b22-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2397198320915042","article-title":"Update on morbidity and mortality in systemic sclerosis-related interstitial lung disease","volume":"6","author":"Volkmann","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"key20221010114626_b23-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: Systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"key20221010114626_b24-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/art.1780370903","article-title":"Severe restrictive lung disease in systemic sclerosis","volume":"37","author":"Steen","year":"1994","journal-title":"Arthritis Rheum"},{"key":"key20221010114626_b25-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"key20221010114626_b26-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"key20221010114626_b27-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.autrev.2013.09.006","article-title":"Breast cancer in systemic sclerosis: Results of a cross-linkage of an Italian rheumatologic center and a population-based cancer registry and review of the literature","volume":"13","author":"Colaci","year":"2014","journal-title":"Autoimmun Rev"},{"key":"key20221010114626_b28-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/art.1780360405","article-title":"Cancer in systemic sclerosis","volume":"36","author":"Abu-Shakra","year":"1993","journal-title":"Arthritis Rheum"},{"key":"key20221010114626_b29-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.autrev.2012.02.021","article-title":"Malignancies associated with systemic sclerosis","volume":"11","author":"Szekanecz","year":"2012","journal-title":"Autoimmun Rev"},{"key":"key20221010114626_b30-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1540-9740.2006.04448.x","article-title":"Breast cancer and scleroderma","volume":"5","author":"Scope","year":"2006","journal-title":"Skinmed"},{"key":"key20221010114626_b31-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/ard.62.8.728","article-title":"Risk of cancer in patients with scleroderma: A population based cohort study","volume":"62","author":"Hill","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"3112","key":"key20221010114626_b32-MCO-17-4-02578","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03112","article-title":"Intriguing relationships between cancer and systemic sclerosis: Role of the immune system and other contributors","volume":"9","author":"Maria","year":"2019","journal-title":"Front Immunol"},{"key":"key20221010114626_b33-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/rheumatology\/36.4.426","article-title":"High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis","volume":"36","author":"Straub","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"25998","key":"key20221010114626_b34-MCO-17-4-02578","doi-asserted-by":"publisher","DOI":"10.1038\/srep25998","article-title":"Plasma prolactin and breast cancer risk: A meta-analysis","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"key20221010114626_b35-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jamainternmed.2013.9071","article-title":"Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years","volume":"173","author":"Li","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"e0159672","key":"key20221010114626_b36-MCO-17-4-02578","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159672","article-title":"The use of antihypertensive medication and the risk of breast cancer in a case-control study in a spanish population: The MCC-spain study","volume":"11","author":"G\u00f3mez-Acebo","year":"2016","journal-title":"PLoS One"},{"key":"key20221010114626_b37-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.autrev.2014.03.003","article-title":"Systemic sclerosis, breast cancer and calcium channel blockers: A new player on the scene?","volume":"13","author":"Bernal-Bello","year":"2014","journal-title":"Autoimmun Rev"},{"key":"key20221010114626_b38-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1055-9965.EPI-17-0096","article-title":"Use of calcium channel blockers and breast cancer risk in the women's health initiative","volume":"26","author":"Brasky","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20221010114626_b39-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/ard.42.4.368","article-title":"The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: A controlled retrospective follow-up","volume":"42","author":"Baltus","year":"1983","journal-title":"Ann Rheum Dis"},{"key":"key20221010114626_b40-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3899\/jrheum.080611","article-title":"Squamous cell carcinomas in 2 patients with diffuse scleroderma treated with mycophenolate mofetil","volume":"36","author":"Gulamhusein","year":"2009","journal-title":"J Rheumatol"},{"key":"key20221010114626_b41-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/bjd.13899","article-title":"Glycosaminoglycan and versican deposits in taxane-induced sclerosis","volume":"173","author":"Okada","year":"2015","journal-title":"Br J Dermatol"},{"key":"key20221010114626_b42-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/toxsci\/kfv017","article-title":"Docetaxel facilitates endothelial dysfunction through oxidative stress via modulation of protein kinase C beta: The protective effects of sotrastaurin","volume":"145","author":"Hung","year":"2015","journal-title":"Toxicol Sci"},{"key":"key20221010114626_b43-MCO-17-4-02578","first-page":"1601","article-title":"Exaggerated fibrosis in patients with systemic sclerosis (scleroderma) following radiation therapy","volume":"20","author":"Abu-Shakra","year":"1993","journal-title":"J Rheumatol"},{"key":"key20221010114626_b44-MCO-17-4-02578","first-page":"2265","article-title":"De novo systemic sclerosis after radiotherapy: A report of 3 cases","volume":"26","author":"Darras-Joly","year":"1999","journal-title":"J Rheumatol"},{"key":"key20221010114626_b45-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/acr.23505","article-title":"Impact of radiation therapy on scleroderma and cancer outcomes in scleroderma patients with breast cancer","volume":"70","author":"Shah","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key20221010114626_b46-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/ijd.14067","article-title":"Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature","volume":"57","author":"Verhulst","year":"2018","journal-title":"Int J Dermatol"},{"key":"key20221010114626_b47-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2133.2006.07597.x","article-title":"Taxane-induced scleroderma","volume":"156","author":"Itoh","year":"2007","journal-title":"Br J Dermatol"},{"key":"key20221010114626_b48-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"106","DOI":"10.5114\/pdia.2017.67054","article-title":"The first case of drug-induced pseudoscleroderma and eczema craquel\u00e9 related to nab-paclitaxel pancreatic adenocarcinoma treatment","volume":"35","author":"Soko\u0142owska-Wojdy\u0142o","year":"2018","journal-title":"Postepy Dermatol Alergol"},{"key":"key20221010114626_b49-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1684\/ejd.2016.2763","article-title":"Scleroderma-like skin changes occurring after the use of paclitaxel without any chemical solvents: A first case report","volume":"26","author":"Shibao","year":"2016","journal-title":"Eur J Dermatol"},{"key":"key20221010114626_b50-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/1097-0142(19950701)76:1<110::aid-cncr2820760117>3.0.co;2-9","article-title":"Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases","volume":"76","author":"Battafarano","year":"1995","journal-title":"Cancer"},{"key":"key20221010114626_b51-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","article-title":"Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis","volume":"37","author":"Hamaguchi","year":"2010","journal-title":"J Dermatol"},{"key":"key20221010114626_b52-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1089\/hyb.1984.3.223","article-title":"Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors","volume":"3","author":"Kufe","year":"1984","journal-title":"Hybridoma"},{"key":"key20221010114626_b53-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.resinv.2016.09.003","article-title":"Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis","volume":"55","author":"Wakamatsu","year":"2017","journal-title":"Respir Investig"},{"key":"key20221010114626_b54-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10408360490452040","article-title":"MUC1 and the MUCs: A family of human mucins with impact in cancer biology","volume":"41","author":"Baldus","year":"2004","journal-title":"Crit Rev Clin Lab Sci"},{"key":"key20221010114626_b55-MCO-17-4-02578","first-page":"138","article-title":"CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases","volume":"27","author":"Kruit","year":"2010","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"key20221010114626_b56-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10147-008-0773-3","article-title":"Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer","volume":"13","author":"Uehara","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"key20221010114626_b57-MCO-17-4-02578","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2521::AID-CNCR17>3.0.CO;2-A","article-title":"Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma","volume":"83","author":"Shering","year":"1998","journal-title":"Cancer"},{"issue":"e0133830","key":"key20221010114626_b58-MCO-17-4-02578","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133830","article-title":"Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer","volume":"10","author":"Shao","year":"2015","journal-title":"PLoS One"},{"key":"key20221010114626_b59-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.12659\/msm.896563","article-title":"Assessing clinical significance of serum CA15-3 and carcinoembryonic antigen (CEA) levels in breast cancer patients: A meta-analysis","volume":"22","author":"Fu","year":"2016","journal-title":"Med Sci Monit"},{"key":"key20221010114626_b60-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cca.2014.11.001","article-title":"Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer","volume":"440","author":"Di Gioia","year":"2015","journal-title":"Clin Chim Acta"},{"key":"key20221010114626_b61-MCO-17-4-02578","first-page":"498","article-title":"Elevation of serum Ca 15-3 antigen: An early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases","volume":"58","author":"Wojtacki","year":"2001","journal-title":"Przegl Lek"},{"key":"key20221010114626_b62-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10549-005-9155-y","article-title":"Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients","volume":"98","author":"Tampellini","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"key20221010114626_b63-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1684\/abc.2008.0244","article-title":"Routine use of serial plasmatic CA 15-3 determinations during the follow-up of patients treated for breast cancer. Evaluation as factor of early diagnosis of recurrence","volume":"66","author":"Chourin","year":"2008","journal-title":"Ann Biol Clin (Paris)"},{"key":"key20221010114626_b64-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"7549","DOI":"10.3892\/ol.2017.7164","article-title":"Elevation of serum CEA and CA15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients","volume":"14","author":"Yang","year":"2017","journal-title":"Oncol Lett"},{"key":"key20221010114626_b65-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10549-009-0377-2","article-title":"Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer","volume":"118","author":"Kim","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"key20221010114626_b66-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/00124743-200208000-00005","article-title":"Transient elevation of the tumor markers CA 15-3 and CASA as markers of interstitial lung disease rather than underlying malignancy in dermatomyositis sine myositis","volume":"8","author":"Wong","year":"2002","journal-title":"J Clin Rheumatol"},{"key":"key20221010114626_b67-MCO-17-4-02578","first-page":"220","article-title":"Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers","volume":"3","author":"Inagaki","year":"2009","journal-title":"Biosci Trends"},{"key":"key20221010114626_b68-MCO-17-4-02578","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jaut.2008.08.008","article-title":"Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: Associations with organ manifestations, immunolaboratory markers and disease activity indices","volume":"31","author":"Szekanecz","year":"2008","journal-title":"J Autoimmun"},{"key":"key20221010114626_b69-MCO-17-4-02578","first-page":"4069","article-title":"Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer","volume":"6","author":"Ogawa","year":"2000","journal-title":"Clin Cancer Res"},{"key":"key20221010114626_b70-MCO-17-4-02578","first-page":"151","article-title":"Serum marker KL-6\/MUC1 for the diagnosis and management of interstitial pneumonitis","volume":"46","author":"Kohno","year":"1999","journal-title":"J Med Invest"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T08:46:38Z","timestamp":1665391598000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2022.2578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":70,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,8,8]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2022.2578","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"article-number":"145"}}